Kodiak reports Q2 2026 results, confirms three Phase 3 readouts by year-end

Kodiak Sciences reported business highlights and financial results for the quarter ended June 30, 2026 on August 13, 2026. CEO Victor Perlroth said the company remains on track for September 2026 DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by December 2026 PEAK Phase 3 Pivotal Analysis 1 topline results evaluating KSI-101 in Macular Edema Secondary to Inflammation.¹

During the quarter, Kodiak completed enrollment of the first 300-patient cohort supporting Pivotal Analysis 1 of the Phase 3 PEAK study, initiated patient enrollment in the Phase 3 ALTO study of KSI-501 in Diabetic Macular Edema, and continued BLA preparation activities for Zenkuda.¹

The company said the approximately 910-patient ALTO study is designed to demonstrate superiority of KSI-501 versus aflibercept and represents the second registrational Phase 3 study of KSI-501, following DAYBREAK in wet AMD.¹ For PEAK, completion of enrollment in the second pivotal cohort evaluating 600 subjects across PEAK and PINNACLE supporting Pivotal Analysis 2 is expected in the fourth quarter of 2026, with topline data anticipated in the second quarter of 2027.¹

On finances, Kodiak ended the second quarter of 2026 with $125.9 million of cash and cash equivalents,¹ down from $209.862 million at year-end 2025 per the balance sheet data. The company said it expects that its current cash and cash equivalents will support its current and planned operations into 2027.¹

Net loss for the quarter was $65.6 million, or $1.05 per share on a basic and diluted basis, as compared to a net loss of $54.3 million, or $1.03 per share on a basic and diluted basis, for the second quarter of 2025.¹